The clinical-stage biopharmaceutical company highlighted in today’s article is focused on the development of novel therapies for cardio-metabolic disease, liver disease, ophthalmic disease and cancer – and while it has yet to actually turn a profit, it generated over $103 million in revenue in 2019 (the year it IPOed), has lots of cash on hand, and perhaps most importantly, has seen significant insider buying lately. For the biotech in question – and potential action to take – CLICK HERE.